John Kerry's Official Campaign 2004 Position on Biotech:
Common Sense Approach To Biotechnology

John Kerry wants to work towards the goal of reducing the ecological footprint of agriculture and ensuring adequate and safe food and sustainability. As Iowa Nobel laureate Norman Borlaug's* work has proven, genetically modified crops are part of the way we will achieve that goal. John Kerry supports farmers' rights to use safe, approved, and regulated technologies.

• Regulation. As president, John Kerry will redouble government efforts to make sure biotechnology is safe for human consumption and safe for the environment. He will give government agencies the power they need to effectively regulate genetically modified food products, both before and after market.
  
  
• Foreign Policies. As president, John Kerry will work with the international community to effectively address concerns about genetically modified products and improve trade relations.

source: http://www.johnkerry.com/pdf/pr_2004_0703.pdf and http://www.johnkerry.com/issues/rural/farmers.html 21oct04

Mindfully.org note:
Norman Borlaug is the mentor of the "Green Revolution." What is interesting is that he now thinks it was flawed...   but that genetic engineering can now correct the problems of that previous technology, which he promised would solve the problem of hunger in throughout the world.

Please read "The Green Revolution" and "Will Genetically Engineered Foods Feed the World?"

It would seem that Kerry's common sense approach is to invest — see below

Genetic Engineering News
v.24, n.16, 15sep04 

Poll Results

Genetic Engineering News is a biotech industry magazine 

United States Senate Financial Disclosure Report for 
Annual and Termination Reports 
KERRY, JOHN F. 15may03

Calendar Year Covered by Report: 2002

Mindfully.org note: The figures here are only for those listed specifically as Biotech and/or BioPharm and do not include investments in Pharmaceuticals, which would nearly all involve the manufacturing and/or use of Biotech organisms.

Identity of Non-Publicly Traded Assets Unearned Income Sources
_______________________________________________________________

Afferon Corp, Wayne, PA (Biotech/BioPharm) 			$  50,000 - $   100,000
Melanotan/Epilan, Melbourne, AU (Biotech/BioPharm) 		$   1,100 - $    15,000
Salmedlx, Inc. (Biotech) 					$ 100,000 - $   250,000
Alnylam Pharmaceuticals Inc., Cambridge, MA (Biotech/BioPharm) 	$  15,000 - $    50,000
Anagen Therapeutics Inc., Northbrook, IL (Biotech/BioPharm) 	$   1,100 - $    15,000
E-M Logix, Inc., Brighton, MA (Biotech/BioPharm) 		$  15,000 - $    50,000
Genecraft Inc., Seattle, WA (Biotech/BioPharm) 			$  15,000 - $    50,000
NeurogesX, Inc., San Carlos, CA (Biotech/Biopharm) 		$  50,000 - $   100,000
Rexagen Corp., Seattle, WA (Biotech/BioPharm) 			$  15,000 - $    50,000
Surface Logix, Inc., Brighton, MA (Biotech/BioPharm) 		$  15,000 - $    50,000
Alnylam Pharmaceuticals Inc. (Biotech/BioPharm) 		$  15,000 - $    50,000
Athenix Corporation (Biotech/BioPharm) 				$  15,000 - $    50,000
Hydra Biosciences Inc., (Biotech/BioPharm) 			$   1,100 - $    15,000
Momenta Pharmaceuticals (Biotech/BioPharm) 			$  15,000 - $    50,000
Saegis Pharmaceuticals (Biotech/BioPharm) 			$  15,000 - $    50,000
Abbott Labs 							$   1,100 - $    15,000
Monsanto 							$   1,100 - $    15,000
Novartis 				none or less than $1,000 
Arcturus Engineering, Inc. (Biotech/BioPharm) 			$   1,100 - $    15,000
Cytokinetics, Inc. (Biotech/BioPharm) 				$   1,100 - $    15,000
Active Bionics Inc. (Biotech) 					$ 100,000 - $   250,000
Picoliter (Biotech/BioPharm) 					$ 100,000 - $   250,000
PTC (Biotech/BioPharm) 						$ 100,000 - $   250,000
Salmedix, Inc. (Biotech) 					$ 100,000 - $   250,000
Anagen Therapeutics Inc., Northbrook, IL (Biotech/BioPharm) 	$   1,100 - $    15,000
Elixir Pharmaceuticals, Inc., Cambridge MA (Biotech/BioPharm) 	$  15,000 - $    50,000
_______________________________________________________________ 

H.J. Heinz II Marital Trust
Afferon Corp, Wayne, PA (Biotech/Biopharm) 			$  50,000 - $   100,000
Melanotan/Epilan, Melbourne, AU (Biotech/BioPharm) 		$   1,100 - $    15,000
_______________________________________________________________

H.J. Heinz III Marital Trust

Del Monte Foods Inc. 					   		Over $1,000,000
Heinz, HJ Co 						   		Over $1,000,000
Biomet Inc 						   		Over $1,000,000
Intel Corp 							$  501,000 - $1,000,000
Nokia Corp Sponsored ADR 				   		Over $1,000,000
Pfizer Inc 						   		Over $1,000,000
Walgreen Co 						   		Over $1,000,000

				      Total of Minimum of over $7 Million 
					invested in biotech not counting 
					pharmaceuticals companies in 2003
_______________________________________________________________

source: http://www.johnkerry.com/pdf/FD_02.pdf 20oct04

Mindfully.org note:
Biotech investments pretty bad, but this guy holds a veritable cornucopia of wealth in corporations that someone who has the future of our children in mind would stay away from. Mindfully.org is not advocating one or another candidate, but we think you should at least know the truth. So in all fairness, Bush would be in about the same position, give or take a few million. What's a few million when trillions are at stake? The answer is: Everything a decent society is based on.